Stock analysts at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a "buy" rating on the biotechnology company's stock.
Several other research analysts also recently weighed in on ADAP. Scotiabank cut their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research report on Friday, March 21st. Finally, Guggenheim decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $1.83.
Get Our Latest Analysis on ADAP
Adaptimmune Therapeutics Price Performance
ADAP traded up $0.06 during midday trading on Friday, reaching $0.31. 6,750,772 shares of the company's stock were exchanged, compared to its average volume of 1,765,311. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.48. The stock has a market capitalization of $78.46 million, a PE ratio of -1.39 and a beta of 2.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The business's 50-day moving average price is $0.49 and its 200 day moving average price is $0.65.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. As a group, equities analysts anticipate that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.
Institutional Investors Weigh In On Adaptimmune Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 28,526 shares during the period. Two Sigma Advisers LP boosted its holdings in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 58,787 shares during the last quarter. Two Sigma Investments LP grew its position in Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 19,146 shares during the period. Virtu Financial LLC grew its position in Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 21,688 shares during the period. Finally, LPL Financial LLC increased its stake in Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 94,623 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Further Reading
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
